Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642-59.

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.

Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol. 1989;24(3):269-76.

D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-31.

Davies S. Chief Medical Officer annual report 2011: the public's health. 2011 [cited 2018 Oct 31]; Available from: https://www.gov.uk/government/publications/cmo-annual-report-2011-volume-one-on-the-state-of-the-public-s-health.

Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, Duvaldestin P. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology. 1985;62(4):480-4.

Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. British journal of anaesthesia. 1982;54(12):1267-70.

Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289-97.

Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology. 1987;7(4):660-4.

Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189-206.

LaFond JP, Shah NL. Bursting with symptoms: A review of palliation of ascites in cirrhosis. Clin Liver Dis. 2016;8(1):10-2.

Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, Taburet AM. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br J Clin Pharmacol. 1991;31(2):185-7.

Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120(1):170-8.

NICE. Palliative care for adults: strong opioids for pain relief. 2012 [cited 2018 Oct 31]; Available from: https://www.nice.org.uk/guidance/cg140/resources/palliative-care-for-adults-strong-opioids-for-pain-relief-pdf-35109564116677.

North-Lewis P. Drugs and the Liver. A guide to drug handling in liver dysfunction. 1st ed: Pharmaceutical Press; 2008.

Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989;29(3):272-7.

Phoolchund A, Murray S, Hogan B, O'Beirne J. Outcome Of Patients Considered Unsuitable For Liver Transplantation – A Missed Opportunity For Palliative Care? Gut. 2014;63(Suppl 1):A17.

Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol. 2014;12(4):692-8.

Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. Journal of palliative medicine. 2014;17(11):1271-7.

Reinglas J, Amjadi K, Petrcich B, Momoli F, Shaw-Stiffel T. The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX ((c)) Catheter. Can J Gastroenterol Hepatol. 2016;2016:4680543.

Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997;61(6):655-61.

The Scottish Public Health Observatory. Chronic liver disease: key points. 2018 [cited 2018 Oct 31]; Available from: https://www.scotpho.org.uk/health-wellbeing-and-disease/chronic-liver-disease/key-points/.

Twycross R, Wilcock A, Howard P. Palliative Care Formulary PCF6. 6th ed. England: Pharmaceutical Press; 2017.

Watson M, Armstrong P, Gannon C, Sykes N, Back I. Analgesia in Liver Disease. 2016 [cited 2018 Oct 31]; Available from: http://book.pallcare.info/index.php?tid=227.

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, et al. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2018;391(10125):1097-107.